D.E. Shaw & Co’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-5,544
| Closed | -$300K | – | 4738 |
|
|
2025
Q4 | $272K | Buy |
+5,544
| New | +$259K | ﹤0.01% | 4198 |
|
|
2025
Q1 | – | Sell |
-114,110
| Closed | -$4.18M | – | 4436 |
|
|
2024
Q4 | $3.86M | Sell |
114,110
-8,746
| -7% | -$315K | ﹤0.01% | 2192 |
|
|
2024
Q3 | $5.02M | Buy |
+122,856
| New | +$5.03M | ﹤0.01% | 1945 |
|
|
2023
Q4 | – | Sell |
-25,200
| Closed | -$914K | – | 4422 |
|
|
2023
Q3 | $914K | Sell |
25,200
-194,461
| -89% | -$6.9M | ﹤0.01% | 3118 |
|
|
2023
Q2 | $7.83M | Buy |
+219,661
| New | +$7.88M | 0.01% | 1539 |
|
|
2022
Q3 | – | Sell |
-94,208
| Closed | -$3.57M | – | 5314 |
|
|
2022
Q2 | $5.13M | Sell |
94,208
-309,742
| -77% | -$17.1M | 0.01% | 2094 |
|
|
2022
Q1 | $22M | Sell |
403,950
-183,114
| -31% | -$9.95M | 0.02% | 966 |
|
|
2021
Q4 | $32.4M | Buy |
587,064
+575,313
| +4,896% | +$29.9M | 0.03% | 781 |
|
|
2021
Q3 | $561K | Buy |
11,751
+3,971
| +51% | +$199K | ﹤0.01% | 4017 |
|
|
2021
Q2 | $387K | Buy |
+7,780
| New | +$374K | ﹤0.01% | 4152 |
|
|
2021
Q1 | – | Sell |
-44,436
| Closed | -$2.02M | – | 4220 |
|
|
2020
Q4 | $2.04M | Sell |
44,436
-581,196
| -93% | -$26.7M | ﹤0.01% | 2540 |
|
|
2020
Q3 | $29.4M | Buy |
625,632
+516,182
| +472% | +$25.9M | 0.03% | 644 |
|
|
2020
Q2 | $5.58M | Sell |
109,450
-563,768
| -84% | -$28.9M | 0.01% | 1583 |
|
|
2020
Q1 | $31.9M | Buy |
+673,218
| New | +$35.9M | 0.05% | 424 |
|
|
2019
Q2 | – | Sell |
-227,741
| Closed | -$11.9M | – | 3732 |
|
|
2019
Q1 | $11.9M | Sell |
227,741
-201,939
| -47% | -$10.1M | 0.02% | 999 |
|
|
2018
Q4 | $20.5M | Buy |
+429,680
| New | +$21.2M | 0.03% | 699 |
|
|
2018
Q1 | – | Sell |
-262,968
| Closed | -$12.2M | – | 3596 |
|
|
2017
Q4 | $11.7M | Sell |
262,968
-210,678
| -44% | -$9.73M | 0.02% | 942 |
|
|
2017
Q3 | $24M | Buy |
473,646
+356,753
| +305% | +$18.1M | 0.04% | 540 |
|
|
2017
Q2 | $6.3M | Buy |
116,893
+22,873
| +24% | +$1.22M | 0.01% | 1173 |
|
|
2017
Q1 | $4.96M | Sell |
94,020
-1,240,452
| -93% | -$62.9M | 0.01% | 1306 |
|
|
2016
Q4 | $64.2M | Buy |
+1,334,472
| New | +$65.9M | 0.11% | 222 |
|
|
2016
Q2 | – | Sell |
-370,460
| Closed | -$18.8M | – | 3399 |
|
|
2016
Q1 | $18.8M | Buy |
+370,460
| New | +$18.5M | 0.03% | 566 |
|
|
2015
Q4 | – | Sell |
-8,266
| Closed | -$421K | – | 3872 |
|
|
2015
Q3 | $397K | Sell |
8,266
-1,559,690
| -99% | -$81.2M | ﹤0.01% | 3209 |
|
|
2015
Q2 | $81.6M | Buy |
1,567,956
+1,439,798
| +1,123% | +$81.1M | 0.12% | 192 |
|
|
2015
Q1 | $7.39M | Sell |
128,158
-737,948
| -85% | -$42.3M | 0.01% | 1141 |
|
|
2014
Q4 | $46.3M | Buy |
866,106
+437,323
| +102% | +$24.5M | 0.06% | 378 |
|
|
2014
Q3 | $24.6M | Buy |
+428,783
| New | +$26.3M | 0.03% | 604 |
|
|
2014
Q2 | – | Sell |
-43,788
| Closed | -$2.92M | – | 4328 |
|
|
2014
Q1 | $2.92M | Buy |
+43,788
| New | +$2.96M | ﹤0.01% | 2019 |
|
|
2013
Q3 | – | Sell |
-16,696
| Closed | -$1.04M | – | 4352 |
|
|
2013
Q2 | $1.04M | Buy |
+16,696
| New | +$1.06M | ﹤0.01% | 2674 |
|
Other funds holding GSK
JEST
D.E. Shaw & Co's GSK Position: Q1 2026 in Review
D.E. Shaw & Co sold out of GSK (GSK) in Q1 2026, closing a stake of 5,544 shares — an estimated $300K sold.
D.E. Shaw & Co first reported a position in GSK in Q2 2013 and held it in 29 quarters. The position peaked at $81.6M in Q2 2015. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- D.E. Shaw & Co reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
- D.E. Shaw & Co sold 5,544 GSK shares in Q1 2026, an estimated $300K.
- D.E. Shaw & Co first reported a position in GSK in Q2 2013 and held it in 29 quarters.
- D.E. Shaw & Co's GSK position peaked at $81.6M in Q2 2015.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.